semaglutide fda approval weight loss The approved a pill version of the GLP-1 receptor agonist (Wegovy), making it the first oral GLP-1 agent indicated for loss, Novo Nordisk announced on Monday. The once-daily 25 FDA approves higher dose of

Whilst these medicines offer significant therapeutic benefits, some patients report experiencing an unpleasant taste in their mouth during treatmentoften described as metallic, bitter, or simply 'off'

Exercise helps burn calories and improves overall health by boosting metabolism and enhancing mood

Yet, the stalling part, or the plateau, is essential the scales arent moving because our body is adjusting to change

So, if youre thinking about giving this a shot, take it slow, listen to your body, and keep your doctor in the loop

Some common Wegovy side effects include: Vomiting Nausea Diarrhea Stomach pain Bloating and gas Constipation Gastroesophageal reflux disease (GERD) Injection site reactions These may be worse when you start taking it or increase your dose